In patients with shorter duration of diabetes, GLP1-RA monotherapy has been shown to improve beta-cell function as compared to placebo20, 21 but, to our knowledge, the metabolic effects of its combination with basal insulin have not been evaluated in this setting. The gene discussed is INS; the disease is diabetes mellitus.